Adeka (4401) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
23 Oct, 2026Executive summary
Nine-month net sales rose 3.5% YoY to ¥296,384 million; operating profit rose 25.1% to ¥30,081 million and profit attributable to owners of parent rose 16.7% to ¥19,208 million.
Profit growth reflected higher sales volume and net pricing; operating profit increased across core businesses, despite lower Food Products and Life Science sales.
Overseas sales ratio was 55.5%.
Financial highlights
Ordinary profit rose 20.7% to ¥29,672 million; basic EPS increased to ¥188.42 from ¥161.01.
Gross profit increased to ¥84,034 million from ¥73,898 million.
Total assets were ¥547,714 million, net assets ¥350,120 million and capital adequacy ratio 53.9%.
Cash and deposits increased ¥9.8 billion from March to December 2024, while current liabilities decreased ¥12.5 billion.
Outlook and guidance
FY2024 forecast unchanged: net sales ¥426 billion, operating profit ¥41.1 billion, ordinary profit ¥39.2 billion and profit attributable to owners of parent ¥24.5 billion.
FY2024 dividend forecast is ¥97 per share, comprising ¥48 interim and ¥49 year-end; FY2023 dividend was ¥90.
Electronic materials operating profit forecast was cut from ¥11.9 billion to ¥11 billion after delayed China adoption of optical-film photo-curing materials; other segments offset the shortfall, leaving total guidance unchanged.
ADX 2026 targets: net sales ¥500 billion, operating profit ¥53 billion, ROE 11% and ROIC 10.5%.
Latest events from Adeka
- Q1 earnings fell on volume weakness; FY profit targets stayed intact.document-source184401
Q1 2024 - Record FY2023 profits set the stage for ADX 2026 growth and JPY 75 billion in CapEx.4401
Q4 2024 - Pricing and FX cushioned volume-led pressure as FY2023 guidance remained unchanged.4401
Q3 2024 - Strong sales and profit growth led by chemicals and semiconductors; outlook and dividends raised.4401
Q1 2027 - Record FY2025 results; FY2026 forecasts further growth but exclude Middle East impacts.4401
Q4 2026 - H1 growth lifted FY2024 guidance and dividends, led by Chemicals.4401
Q2 2025 - Record FY2024 results, with FY2025 growth forecast amid tariff and cost risks.4401
Q4 2025 - Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 2026 - Profit rose on strong Life Science and Environmental Materials, offsetting Chemicals weakness.4401
Q3 2026